LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
Podcasts & Webcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
BioCentury-BayHelix China Healthcare Summit
East-West Healthcare Reception
BioCentury-BayHelix East-West Summit
Bio€quity Europe
BioCentury Grand Rounds Inquiry
The BioCentury Show
Webinars - Upcoming & On-Demand
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a product name.
REQUEST A FREE TRIAL
Product
Deals
Articles
BioCentury
|
Mar 6, 2021
Product Development
The pace of new modality approvals is picking up
Close to 30 new modality drugs approved in the last five years, and about 50 in registrational trials
Read More
BioCentury
|
Mar 16, 2018
Clinical News
Adaptimmune reports early Phase I/II liposarcoma data for NY-ESO SPEAR T cells
Read More
BioCentury
|
Jun 15, 2017
Clinical News
Adaptimmune starts Phase I of T cell therapy plus Keytruda
Read More
BioCentury
|
Dec 14, 2016
Clinical News
NY-ESO-SPEAR T-cell therapy: Ph I/II started
Read More
BioCentury
|
Oct 17, 2016
Clinical News
NY-ESO SPEAR T-cell therapy: Phase I/IIa amended
Read More
BioCentury
|
Aug 15, 2016
Clinical News
NY-ESO SPEAR T-cell therapy: Pivotal trial hold
Read More
BioCentury
|
Aug 15, 2016
Finance
Serving returns
How Ally Bridge expects to build on top of WuXi arbitrage play
Read More
BioCentury
|
Aug 8, 2016
Clinical News
Enhanced T-cell therapy targeting NY-ESO-1 regulatory update
Read More
BioCentury
|
Feb 22, 2016
Clinical News
Enhanced T-cell therapy targeting NY-ESO-1 regulatory update
Read More
BioCentury
|
Dec 7, 2015
Clinical News
Enhanced T-cell therapy targeting NY-ESO-1: Phase I/II started
Read More
Items per page:
10
1 - 10 of 12